| Douglas Mcclure, RPH | |
|
6710 W Bethany Home Rd, Glendale, AZ 85303-4402 | |
| (623) 934-9243 | |
| (623) 907-4990 |
| Full Name | Douglas Mcclure |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 6710 W Bethany Home Rd, Glendale, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013304476 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S014143 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Mcclure, RPH 500 S 99th Ave, Tolleson, AZ 85353-9700 Ph: (623) 907-4932 | Douglas Mcclure, RPH 6710 W Bethany Home Rd, Glendale, AZ 85303-4402 Ph: (623) 934-9243 |
News Archive
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.
From 2003 to 2013, the percentage of nonmedical use of prescription opioids decreased among adults in the U.S., while the prevalence of prescription opioid use disorders, frequency of use, and related deaths increased, according to a study in the October 13 issue of JAMA.
Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any potentially dangerous side effects. Investigators from the University of Illinois at Urbana-Champaign report that they have assembled a new cancer drug delivery system that, in cell culture, achieves all of the above.
This episode kicks off with a wild ride: How one journalist nearly got roped into a scam.
› Verified 3 days ago
Dr. William G Dobbin, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5895 W Peoria Ave, Glendale, AZ 85302 Phone: 623-934-9152 | |
Meridith Amber Yannace, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4315 W Bell Rd, Glendale, AZ 85308 Phone: 602-938-2600 | |
Jennifer Ahrum Yang, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4965 W Bell Rd, Glendale, AZ 85308 Phone: 602-843-2305 | |
Amy Sa Nguyen, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9009 N 67th Ave, Glendale, AZ 85302 Phone: 623-931-5169 | |
Stacie Rika Danielson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4965 W Bell Rd, Glendale, AZ 85308 Phone: 602-843-2305 | |
Dr. Molly Ubiparipovic, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5011 W Union Hills Dr, Glendale, AZ 85308 Phone: 602-896-0257 |